Intermolecular IMI announces its next round of earnings Monday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement.
Earnings and Revenue
Based on management's projections, Intermolecular analysts model for earnings of 1 cent per share on sales of $10 million.
Intermolecular EPS in the same period a year ago came in at a loss of 5 cents. Sales were $8 million. Revenue would be up 23.62 percent on a year-over-year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | -0.02 | -0.02 | -0.05 | -0.07 |
| EPS Actual | -0.01 | 0.01 | -0.03 | -0.05 |
Stock Performance
Over the last 52-week period, shares are up 49.98 percent. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release. Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. Analysts have been rating Intermolecular stock as Sell. The strength of this rating has dwindled over the past three months.
Conference Call
Intermolecular's Q2 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here: http://ir.intermolecular.com/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
